Polaris AI Pharma announced on July 16 that Quadmedicine, a bio-platform company in which it has made a strategic investment, has submitted a preliminary review application for KOSDAQ listing to the Korea Exchange.
Quadmedicine is a bio company whose core competency lies in its 'Microneedle' platform, a technology for transdermal drug delivery. The microneedle method is gaining attention as a next-generation drug delivery technology because it causes less pain and fewer side effects compared to conventional injections, and it is advantageous for improving medication adherence.
In particular, Quadmedicine has strengthened its competitiveness by building a pipeline that can be expanded to vaccines, rare diseases, and autoimmune disease therapeutics. The company has demonstrated microneedle-based immunogenicity through joint research with the International Vaccine Institute (IVI), as well as through preclinical studies utilizing vaccines under development by the GSK-affiliated vaccine research institute GVGH. Based on these results, Quadmedicine has also signed a commercialization agreement with the global pharmaceutical company GSK headquarters, further proving its technological capabilities.
This listing initiative by Quadmedicine is seen as a tangible outcome of Polaris AI Pharma’s technology-focused investment strategy. Polaris AI Pharma invested approximately 1.5 billion KRW in Quadmedicine in 2020. To date, Polaris AI Pharma has made strategic investments totaling about 29.8 billion KRW in 14 promising bio companies.
A representative from Polaris AI Pharma stated, "Quadmedicine's move toward listing is a case where Polaris AI Pharma's proactive investment has paid off," adding, "We plan to prepare not only for profit from our investments but also to establish collaborative systems with our portfolio companies."
The representative continued, "In the long term, we will also do our utmost to discover AI models based on pharmaceutical data."
Meanwhile, Polaris AI Pharma, in collaboration with Polaris Office, is developing 'Askdoc for Pharma,' an AI analysis model specialized for the pharmaceutical and bio sectors. Askdoc for Pharma is a solution that leverages AI to rapidly and accurately analyze large-scale bio data, including academic papers, patents, and clinical information, thereby supporting key decision-making in the early stages of new drug and generic drug development.
Additionally, Polaris AI Pharma aims to create both practical technological innovation and business success across the bio industry by combining its data analysis capabilities with its experience in strategic investment.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
